# Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients

> **NCT00106379** · PHASE4 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 52 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Truvada (tenofovir DF + emtricitabine)
- **DRUG:** Emtriva (emtricitabine)
- **DRUG:** Viread (tenofovir DF)

## Key facts

- **NCT ID:** NCT00106379
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** 52 (—)
- **Last updated:** 2010-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00106379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00106379, "Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00106379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*